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Background-—Hemoglobin A1c (HbA1c), a time-integrated marker of glycemic control, predicts risk of coronary heart disease
(CHD) among diabetics. Few studies have examined HbA1c and risk of CHD among women and men without clinically elevated
levels or previously diagnosed diabetes.
Methods and Results-—We conducted parallel nested case–control studies among women (Nurses’ Health Study) and men (Health
Professionals Follow-up Study). During 14 and 10 years of follow-up, 468 women and 454 men developed incident nonfatal
myocardial infarction (MI) and fatal CHD. Controls were matched 2:1 based on age, smoking, and date of blood draw. For these
analyses, participants with a history of diabetes or HbA1c levels ≥6.5% at baseline were excluded. Compared with HbA1c of 5.0% to
<5.5%, those with an HbA1c of 6.0% to <6.5% had a multivariable-adjusted relative risk (RR) of CHD of 1.90 (95% CI 1.11 to 3.25) in
women and 1.81 (95% CI 1.09 to 3.03) in men. The pooled RR of CHD was 1.29 (95% CI 1.11 to 1.50) for every 0.5%-increment
increase in HbA1c levels and 1.67 (95% CI 1.23 to 2.25) for every 1%-increment increase, with the risk plateauing around 5.0%.
Furthermore, participants with HbA1c levels between 6.0% and <6.5% and C-reactive protein levels >3.0 mg/L had a 2.5-fold higher
risk of CHD compared with participants in the lowest categories of both biomarkers.
Conclusions-—Our ﬁndings suggest that HbA1c is associated with CHD risk among apparently healthy, nondiabetic women and
men and may be an important early clinical marker of disease risk. (J Am Heart Assoc. 2013;2:e000077 doi: 10.1161/
JAHA.112.000077)
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D
iabetes is a well-known risk factor for cardiovascular
disease (CVD),
1 and although the exact mechanisms are
unknown, angiopathy from dysglycemia is likely a primary
cause. Glycated hemoglobin, assessed clinically by hemoglo-
bin A1c (HbA1c), is a time-integrated marker of average blood
glucose concentration increasingly used in the screening for
and management of diabetes, and it is more closely related to
the risk of complications than are single or episodic measures
of glucose levels.
2–4 Despite the clinical utility of HbA1c,
several recent large randomized trials of intensive HbA1c
lowering among high-risk diabetics have not demonstrated
lower risk of macrovascular events.
5–8
Currently, the degree to which mild elevations of HbA1c not
in the diabetic range are associated with risk of coronary
heart disease (CHD) is unclear.
The association between dysglycemia and risk of CVD may
start at levels that are only modestly elevated, well below the
glucose threshold for diabetes.
9,10 The majority of studies
conducted among nondiabetics have included participants
with HbA1c ≥6.5%,
11,12 the threshold set for diabetes
diagnosis by the American Diabetes Association
2 and World
Health Organization.
4 In several studies, the association
between HbA1c and CHD is attenuated and no longer
signiﬁcant after adjustment for well-known cardiovascular
risk factors.
11,13 Thus, it remains unclear whether HbA1c is a
clinically relevant marker of CHD risk in apparently healthy,
nondiabetic populations, or if it is a proxy for dyslipidemia,
hyperinsulinemia, or other metabolic pathways. In the present
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ORIGINAL RESEARCHstudy, we examined the association between HbA1c and risk
of incident CHD in 2 prospective nested case–control studies
of health professionals without diabetes or without HbA1c
concentrations ≥6.5%.
Methods
Study Population
The Nurses’ Health Study (NHS) and the Health Professionals
Follow-Up Study (HPFS) are prospective cohort investigations
among 121 700 female US registered nurses aged 30 to
55 years at baseline in 1976 (NHS) and 51 529 male US
health professionals aged 40 to 75 years at baseline in 1986
(HPFS). Information about health and disease is assessed
biennially, and information about diet is assessed every
4 years via self-administered questionnaires.
14,15 Between
1989 and 1990, a blood sample was requested from all
participants in the NHS, and it was returned from 32 826
women. Similarly, between 1993 and 1995, a blood sample
was returned from 18 225 men in the HPFS. Participants who
provided blood samples were similar to those who did not,
albeit somewhat younger. In the NHS, among women without
CVD or cancer before 1990, we identiﬁed 468 women with
incident nonfatal myocardial infarction (MI) or fatal CHD
between the date of blood draw and June 2004. In the HPFS,
we identiﬁed 454 men with incident nonfatal MI or fatal CHD
between the date of blood draw and return of the 2004
questionnaire. Using risk-set sampling,
16 controls were ran-
domly selected on a 2:1 basis matched for age, smoking, date
of blood draw, and fasting status (women only) from
participants free of CVD at the time the case was diagnosed.
To assess men and women without diabetes, participants with
a history of diabetes or HbA1c levels ≥6.5% at baseline (153
women; 123 men) were excluded from further analyses. We
used 6.5% as the cutoff because this value has been
recommended as a level deﬁning diabetes by the American
Diabetes Association
2 and the World Health Organization
4 and
is the level at which complications of diabetes such as
retinopathy arise.
The study protocol was approved by the Institutional
Review Board of the Brigham and Women’s Hospital and
by the Harvard School of Public Health Human Subjects
Committee Review Board.
Assessment of CHD
MI was conﬁrmed by study physicians blinded to participants’
exposure status if it met World Health Organization criteria
(symptoms plus either diagnostic electrocardiographic
changes or elevated levels of cardiac enzymes).
17,18 Deaths
were identiﬁed from state vital records and the National
Death Index or reported by the participant’s next of kin or the
postal system. Fatal CHD was conﬁrmed by use of hospital
records or on autopsy or if CHD was listed as the cause of
death on the death certiﬁcate, if it was the underlying and
most plausible cause, and if evidence of previous CHD was
available.
Assessment of Other Factors
Anthropometric data, lifestyle behavior, and diet were derived
from the questionnaire administered in 1990 to women and
1994 to men, with missing information substituted from
previous questionnaires. Body mass index (BMI) was calcu-
lated as body weight divided by height squared. Average
nutrient intake was computed using the semiquantitative food
frequency questionnaire. Physical activity was expressed as
metabolic equivalent-hours. The questionnaires and the
validity and reproducibility of measurements have been
previously reported.
15,19
Measurement of Biochemical Variables
Blood samples were collected in liquid sodium heparin blood
tubes for women and EDTA tubes for men, placed on ice packs,
stored in polystyrene foam containers, returned to our
laboratory via overnight courier, and centrifuged and aliquoted
for storage in liquid nitrogen freezers ( 130°C or colder). The
ﬁrst nested case–control set included cases and controls
selected from 1990 to 1998 for NHS and 1994 to 2000 for
HPFS and were previously documented.
20 These samples were
assayed in 2002. Since then, additional nested case–control
sets with follow-up through 2004 have been completed for
both NHS and HPFS and were sent for assaying using similar
methods in 2007. All analyses were performed in a laboratory
certiﬁed by the Centers for Disease Control and Prevention/
National Heart, Lung, and Blood Institute Lipid Standardization
Program with commercially available analytic systems.
HbA1c was measured by turbidimetric immunoinhibition
using packed red cells (Roche Diagnostics), which is a
standard approved by the US National Glycohemoglobin
Standardization Program and the Food and Drug Administra-
tion for clinical use, and traceable to the Diabetes Controls
and Complications Trial. The day-to-day variability at HbA1c
values of 5.5 and 9.1 were 1.9% and 3.0%, respectively. In a
substudy of 83 participants measured 3 years apart, HbA1c
was highly correlated between draws (Spearman=0.88) and
had excellent intraclass correlations (0.73). C-reactive protein
(CRP) concentrations were determined with an immunotur-
bidimetric high-sensitivity assay using reagents and calibra-
tors from Denka Seiken with assay day-to-day variability
between 1% and 2% and were previously shown to be largely
unaffected by transport conditions and to be reproducible
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21,22 Total, high-density lipoprotein
(HDL), and directly assayed low-density lipoprotein choles-
terol and triglycerides were measured using standard meth-
ods with reagents from Roche Diagnostics and Genzyme.
Study samples were sent to the laboratory for analysis in
randomly ordered batches, and the laboratory was blinded to
case–control status. The coefﬁcients of variation for all the
assays were <10%.
Statistical Analyses
We analyzed the 2 cohorts separately. HbA1c levels were
categorized into quintiles based on the sex-speciﬁc distribu-
tions among the controls as well as according to categories
(<5.0%, 5.0% to <5.5%, 5.5% to <6.0%, and 6.0% to <6.5%). In
the categorical analyses, the HbA1c 5.0% to <5.5% category
was used as the reference because there were more
participants than in the <5.0% category. Because of this study
design, the odds ratio derived from the logistic regression
directly estimates the incidence rate (hazard) ratio and, thus,
the RR.
16,23 We analyzed the association between HbA1c levels
and risk of CHD using both conditional and unconditional
logistic regression with adjustment for matching factors and
laboratory batch. Because both analyses provided essentially
the same results, we present unconditional logistic regression,
which parallels the subgroup analyses. In our multivariable
model, we further adjusted for parental history of MI before the
age of 60 (yes/no), alcohol intake (nondrinker; 0.1 to 4.9, 5.0
to 14.9, 15.0 to 29.9, or ≥30.0 g/d; or missing), physical
activity (quintiles), total cholesterol:HDL cholesterol ratio
(quintiles), BMI in categories (<20, 20 to 24.9, 25 to 29.9,
30 to 34.9, and ≥35 kg/m
2), and postmenopausal hormone
therapy (yes/no, women only). Additional adjustment for
hypertension (yes/no) at baseline, triglyceride levels (quin-
tiles), and CRP levels (quintiles) was also conducted. Corre-
lation coefﬁcients were calculated using age-adjusted
Spearman partial correlation coefﬁcients. To test for linear
trend, we used the median HbA1c levels in the control
categories as a continuous variable. In addition, we conducted
analyses per 0.5%-increment increase in HbA1c levels. We
examined the possibly nonlinear relation between HbA1c and
CHD nonparametrically with restricted cubic splines.
24 Tests
for nonlinearity used the likelihood ratio test, comparing the
model with only the linear term to the model with the linear
and the cubic spline terms. To pool the RR estimates for men
and women, we used the weighted average of estimates using
the DerSimonian and Laird random effects model.
25 Because
we are using a single measure of HbA1c to predict future
disease over long-term follow-up, ﬂuctuations in baseline
biological risk factors over time may lead to an underestima-
tion of the true association in the form of “regression dilution
bias.”
26,27 To account for potential changes in our baseline
measure over time, we also present RR estimates corrected for
potential regression dilution bias using the model described by
Clarke et al.
28 In brief, the b coefﬁcients and standard errors
for the entire cohort were divided by the regression dilution
ratio, based on the within-person correlation coefﬁcient
calculated from the subset of participants with repeated
measurements, to obtain the corrected risk estimates for the
usual relation of HbA1c levels and CHD.
All P values presented are 2-tailed, and P values <0.05
were considered statistically signiﬁcant. All analyses were
performed using SAS version 9 (SAS Institute).
Results
Cardiovascular risk factors were higher or more frequent
among the cases compared with the controls in both men and
women (Table 1). As expected, cases were more likely to have
parental history of early MI, history of hypercholesterolemia,
and history of hypertension. Also, cases were more likely to
have higher CRP levels and adverse lipid proﬁles compared
with controls for both women and men. Age-adjusted
Spearman partial correlation coefﬁcients are presented
among controls for women and men (Table 2). HbA1c
percentage was positively correlated with CRP levels, trigly-
cerides:HDL cholesterol ratio, triglycerides, and BMI and
inversely correlated with HDL cholesterol and alcohol intake.
Among participants with HbA1c levels <6.5% and without
history of diabetes at baseline, greater HbA1c levels were
signiﬁcantly associated with an increased risk of CHD in both
women and men. Comparing extreme quintiles of HbA1c
levels, the multivariable-adjusted RR of CHD was 1.70 (95% CI
1.22 to 2.36) in the pooled analysis, with a P for trend of
<0.001 (Table 3). Because additional adjustment for history
of hypertension, triglycerides, and CRP levels did not signif-
icantly attenuate the risk estimates, we refer to model 3 in
multivariable-adjusted and pooled analyses in Table 3.
We further examined the association using ﬁxed cut points.
Compared with HbA1c category 5.0% to <5.5% (reference), the
pooled multivariable-adjusted RRs for CHD were 1.14 (95% CI
0.82 to 1.59) for <5.0%, 1.34 (95% CI 1.08 to 1.68) for 5.5% to
<6.0%, and 1.85 (95% CI 1.28 to 2.69) for 6.0% to <6.5%
(Figure 1). A signiﬁcantly elevated risk of CHD was observed
among nondiabetic women and men with HbA1c levels of
≥5.5%. Even in these populations restricted to lower HbA1c
levels, we found that for every 0.5%-increment increase in
HbA1c levels, the RR of CHD was 1.32 (95% CI 1.05 to 1.65) in
women and 1.27 (95% CI 1.04 to 1.55) in men, and 1.29 (95%
CI 1.11 to 1.50) when pooled. This association did not differ
by health and lifestyle factors such as age, smoking status,
BMI <25 and ≥25 kg/m
2, history of hypertension, or parental
history of early MI (Table S1). We further examined the joint
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categories of HbA1c. Of note, in the lower risk group with CRP
levels ≤3.0 mg/L, a 0.5%-increment increase of HbA1c was
signiﬁcantly associated with risk of incident CHD among
women (RR 1.42, 95% CI 1.04 to 1.94) and men (RR 1.28, 95%
CI 1.03 to 1.60). In pooled analyses, participants in the
highest CRP and HbA1c categories had an RR of CHD of 2.49
(95% CI 1.32 to 4.71) compared with participants in the
lowest of both biomarkers (Figure 2).
A single biomarker at baseline may be a better proxy for
exposure over the ﬁrst several years and possibly become
less correlated with exposure over a longer period. When we
stratiﬁed according to the midpoint of follow-up, the associ-
ation was strongest among cases and controls in the ﬁrst
7 years of follow-up. For every 0.5%-increment increase in
HbA1c levels in the earlier follow-up (<7 years) only, the
multivariable-adjusted RR of incident CHD was 1.39 (95% CI
0.97 to 1.98) for women, 1.33 (95% CI 1.02 to 1.73) for men,
and 1.35 (95% CI 1.09 to 1.67) when we pooled the
estimates. In the later follow-up (≥7 years) only, the corre-
sponding RRs were 1.17 (95% CI 0.90 to 1.52) for women,
1.26 (95% CI 0.92 to 1.72) for men, and 1.20 (95% CI 0.98 to
1.47) when pooled. Finally, when we controlled for regression
dilution bias to account for variability in the baseline measure,
the pooled RR per 0.5% increment was 1.51 (95% CI 1.13 to
2.02) when restricted to the earlier follow-up cycle and 1.42
(95% CI 1.16 to 1.74) for the entire follow-up cycle.
Discussion
In these prospective nested case–control studies in 2 cohorts
of US health professionals, we found that HbA1c was
predictive of CHD risk in participants without diagnosed
Table 1. Baseline Characteristics of Subjects With Incident Myocardial Infarction (Cases) and Matched* Event-Free Controls
Among Women (the Nurses’ Health Study, 14 Years of Follow-up) and Men (the Health Professionals Follow-Up Study, 10 Years of
Follow-up) Without History of Diabetes and Hemoglobin A1c <6.5%
Characteristics
†
Nurses’ Health Study Health Professionals Follow-Up Study
Cases Controls P Value
‡ Cases Controls P Value
‡
N 371 832 396 843
Age, y 59.9 6.6 59.7 6.5 — 64.1 8.8 64.0 8.6 —
Current smokers, % 28.3 26.7 — 9.6 9.1 —
Body mass index, kg/m
2 25.8 4.7 24.9 4.1 0.004 25.9 3.1 25.6 3.3 0.10
Hormone replacement therapy use
among postmenopausal women, %
43.0 45.3 0.76 ———
Parental history of myocardial
infarction before age 60, %
24.5 13.9 <0.001 15.9 11.4 0.03
History of hypercholesterolemia, % 52.3 39.2 <0.001 50.0 41.2 0.004
History of hypertension, % 44.7 25.4 <0.001 34.3 28.5 0.04
NSAID use, % 67.7 69.1 0.62 46.7 43.5 0.29
Total caloric intake, kcal 1796 561 1765 510 0.37 2076 645 2044 642 0.41
Alcohol consumption, g/day 1.1 (0.0 to 6.0) 1.8 (0.0 to 8.8) 0.09 4.7 (0.9 to 15.4) 7.0 (0.9 to 18.3) 0.02
Physical activity, MET-h/wk 12.2 (4.3 to 28.0) 12.4 (5.4 to 25.2) 0.69 22.9 (10.2 to 46.4) 26.9 (12.0 to 48.9) 0.08
HbA1c, % 5.5 (5.2 to 5.7) 5.4 (5.2 to 5.7) 0.01 5.6 (5.3 to 5.8) 5.5 (5.3 to 5.7) 0.01
CRP, mg/L 2.40 (1.07 to 5.44) 1.82 (0.80 to 3.80) <0.001 1.33 (0.58 to 2.59) 0.97 (0.48 to 2.09) <0.001
Total cholesterol, mg/dL 235 40.7 227 40.8 0.001 212 38.3 204 36.2 <0.001
HDL cholesterol, mg/dL 54.0 14.8 60.9 16.7 <0.001 42.9 11.5 46.4 12.7 <0.001
LDL cholesterol, mg/dL 146 37.0 135 37.5 <0.001 135 34.3 127 31.0 <0.001
Triglycerides, mg/dL 115 (82 to 167) 101 (74 to 141) <0.001 139 (94 to 199) 116 (85 to 167) <0.001
Total cholesterol:HDL cholesterol ratio 4.66 1.5 4.00 1.3 <0.001 5.19 1.3 4.66 1.3 <0.001
MET-h indicates metabolic equivalent hours; HbA1c, hemoglobin A1c; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*Matching criteria were age, smoking status, and date of blood draw; in women, additional matching criteria included fasting status.
†Values are mean SD for continuous variables and proportions for categorical variables, except HbA1c, CRP, triglycerides, alcohol, and physical activity, which are shown as median
(interquartile range).
‡P for difference between cases and controls (unadjusted), determined by Student t test for rows with means, by Wilcoxon’s rank sum test for rows with medians, and by v
2 test for rows
with proportions.
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women with an HbA1c of 6.0% to <6.5% had an 85% higher risk
of CHD than those with levels of 5.0% to <5.5%. The positive
association persisted when adjusted for traditional cardiovas-
cular risk factors, including hyperlipidemia, anthropometric
variables, and CRP. Our results suggest that HbA1c is an
important marker of risk across a broad range of levels and
that the causal etiologic pathway may be complex and include
mechanisms other than lipids or inﬂammation.
The relationship of HbA1c with CHD has been studied in
several other nondiabetic populations
11,12,29–32 with incon-
sistent results, possibly due to diverse study protocols, a wide
range of length of follow-up, inconsistent exclusion criteria,
and differences in cohort demographics and outcome deﬁni-
tions. Two previous studies in particular have examined HbA1c
in relation to risk of CHD in participants without diabetes or
clinically elevated HbA1c levels.
13,29 After 7 years of follow-up
in a nested case–control analysis from the WHS, Blake et al
reported an RR of 2.25 (95% CI 1.59 to 3.19) for CVD events
Table 3. Estimated Relative Risks (and 95% CIs) of Myocardial Infarction During Follow-up According to Quintiles of Baseline
Percent Hemoglobin A1c Among Women (Nurses’ Health Study, 14 Years of Follow-up) and Men (the Health Professionals
Follow-Up Study, 10 Years of Follow-up)
Quintile of HbA1c*
P Trend
† 12 3 4 5
Nurses’ Health Study (371 cases/832 controls)
HbA1c,% <5.1 5.1 to <5.3 5.3 to <5.5 5.5 to <5.7 ≥5.7
Cases/controls 62/166 61/168 75/165 84/167 89/166
Model 1
‡ 1.0 1.06 (0.70 to 1.62) 1.43 (0.94 to 2.18) 1.73 (1.12 to 2.66) 2.01 (1.26 to 3.21) <0.001
Model 2
§ 1.0 1.06 (0.69 to 1.65) 1.39 (0.89 to 2.16) 1.59 (1.01 to 2.50) 1.78 (1.09 to 2.91) 0.009
Model 3
¶ 1.0 1.05 (0.68 to 1.63) 1.35 (0.86 to 2.10) 1.55 (0.98 to 2.44) 1.71 (1.04 to 2.80) 0.01
Model 4
k 1.0 1.05 (0.67 to 1.65) 1.39 (0.88 to 2.18) 1.52 (0.96 to 2.43) 1.70 (1.03 to 2.81) 0.02
Health Professionals Follow-Up Study (396 cases/843 controls)
HbA1c,% <5.2 5.2 to <5.4 5.4 to <5.6 5.6 to <5.8 ≥5.8
Cases/controls 64/168 66/169 87/168 73/170 106/168
Model 1
‡ 1.0 1.12 (0.73 to 1.70) 1.56 (1.03 to 2.38) 1.35 (0.87 to 2.11) 1.97 (1.28 to 3.03) 0.001
Model 2
§ 1.0 1.10 (0.71 to 1.68) 1.52 (0.99 to 2.33) 1.19 (0.75 to 1.88) 1.67 (1.07 to 2.59) 0.03
Model 3
¶ 1.0 1.10 (0.72 to 1.69) 1.55 (1.01 to 2.39) 1.19 (0.75 to 1.88) 1.69 (1.08 to 2.64) 0.02
Model 4
k 1.0 1.08 (0.70 to 1.66) 1.57 (1.02 to 2.42) 1.17 (0.74 to 1.86) 1.69 (1.08 to 2.65) 0.02
Pooled
Cases/controls 126/334 127/337 162/333 157/337 195/334
Model 3
¶ 1.0 1.08 (0.79 to 1.46) 1.45 (1.06 to 1.97) 1.36 (0.98 to 1.88) 1.70 (1.22 to 2.36) <0.001
HbA1c indicates hemoglobin A1c; NHS, Nurses’ Health Study; HDL, high-density lipoprotein; CRP, C-reactive protein.
*Quintiles of HbA1c are based on controls in each sex.
†P for trend based on median HbA1c levels in quintiles of the control subjects.
‡Adjusted for age, smoking status, date of blood drawing, fasting status (in NHS only), and laboratory batch.
§Additionally adjusted for family history of myocardial infarction before age of 60 years, alcohol intake, physical activity, nonsteroidal antiinﬂammatory drug use, total cholesterol:HDL
cholesterol ratio, and hormone replacement therapy use among women.
¶Additionally adjusted for body mass index.
kFurther adjusted for hypertension and CRP.
Table 2. Age-Adjusted Spearman Partial Correlation
Coefﬁcients Between Hemoglobin A1c and Cardiovascular Risk
Factors Among Controls in Women (the Nurses’ Health Study)
and Men (the Health Professionals Follow-Up Study)
HbA1c% NHS HPFS
CRP 0.15
‡ 0.13
‡
Total cholesterol 0.04 0.08*
LDL cholesterol 0.04 0.05
HDL cholesterol  0.09
†  0.08*
Total cholesterol:HDL cholesterol ratio 0.09
† 0.11
†
Triglycerides 0.07* 0.12
‡
BMI 0.09
† 0.10
†
Alcohol, g/d  0.03  0.08*
HbA1c indicates hemoglobin A1c; NHS, Nurses’ Health Study; HPFS, Health Professionals
Follow-Up Study; CRP, C-reactive protein; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; BMI, body mass index.
*P<0.05,
†P<0.01,
‡P<0.001.
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tion) comparing the highest (≥5.50%) with the lowest (<5.23%)
quartile of HbA1c.
13 However, this association was attenuated
(RR 1.00; 95% CI 0.65 to 1.54) after adjustment for BMI, blood
pressure, CRP, low-density lipoprotein and HDL cholesterol,
and triglycerides.
13 The authors note that the same results
were observed when the end point of CHD was examined
alone, although with limited power because the CHD analysis
was limited to 136 cases. In a recent analysis from the
Atherosclerosis Risk in Communities (ARIC) study, the risk
factor–adjusted hazard ratios for CHD in participants with
HbA1c of 5.5% to <6.0% and of 6.0% to <6.5% were 1.23
(95% CI 1.07 to 1.41) and 1.78 (95% CI 1.48 to 2.15),
respectively, compared with participants with baseline HbA1c
concentrations of 5.0% to <5.5%.
29 Our results were similar
in magnitude to this study. Furthermore, we showed a
signiﬁcant joint effect of mildly elevated HbA1c and CRP
levels on the risk of incident CHD among nondiabetic men
and women.
Interestingly, we observed a joint association similar to
that of Sander et al,
33 who reported that among nondiabetics,
the combination of elevated HbA1c and CRP was associated
with advanced early carotid atherosclerosis progression and a
3-fold increased risk of major vascular events. This associ-
ation between elevated HbA1c and early atherosclerosis
progression supports the hypothesis that HbA1c may be
causally related to CHD even at low levels.
33 Hyperglycemia,
in addition to diabetes, can lead to the formation of advanced
glycosylated end products, which have been shown to induce
production and secretion of inﬂammatory cytokines.
34 Indeed,
HbA1c has been reported to predict CRP in established
diabetes.
35 In addition, nitric oxide bioavailability, a marker of
intimal reactivity, has been shown to be reduced by both
CRP
36 and HbA1c.
37 This joint effect was observed at even
mildly elevated levels of both biomarkers and may inﬂuence
CHD risk through mechanisms other than diabetes, athero-
sclerosis, and inﬂammation.
A recent meta-analysis
38 examined the association
between HbA1c and risk of CHD in persons without diabetes,
although most studies included participants with HbA1c well
beyond the established clinical threshold of 6.5%. Using data
from 9 cohorts (1639 cases), the meta-analysis reported an
RR of 1.20 (95% Cl 1.10-1.31) for each 1%-increment increase
in levels of HbA1c.
38 This risk estimate was not adjusted for
established CHD risk factors and was weaker than our own.
These differences may be due to the inherent weakness of
meta-analyses, where pooling results from many studies may
lead to random error from differences in lab methods, study
design, and residual confounding. In our nested prospective
studies, the pooled RR of CHD for men and women was 1.67
(95% CI 1.23 to 2.25) per 1%-increment increase in HbA1c,
even after detailed adjustment for other risk factors.
Figure 1. Multivariable-adjusted* relative risk (RR) of incident CHD
among women and men according to categories of HbA1c levels.
*Adjusted for age, smoking status, date of blood draw, fasting status
(in NHS only), laboratory batch, family history of myocardial
infarction before age of 60 years, alcohol intake, physical activity,
NSAID use, total cholesterol:HDL cholesterol ratio, BMI, and
hormone replacement therapy use among women. CHD indicates
coronary heart disease; HbA1c, hemoglobin A1c; NHS, Nurses’ Health
Study; NSAID, nonsteroidal antiinﬂammatory drug; HDL, high-density
lipoprotein; BMI, body mass index.
Figure 2. Multivariable-adjusted* relative risk of incident CHD
among women and men according to categories of HbA1c and clinical
cut points of CRP levels. *Adjusted for age, smoking status, date of
blood draw, fasting status (in NHS only), laboratory batch, family
history of myocardial infarction before age of 60 years, alcohol
intake, physical activity, NSAID use, total cholesterol:HDL cholesterol
ratio, BMI, and hormone replacement therapy use among women.
†P<0.05. CHD indicates coronary heart disease; HbA1c, hemoglobin
A1c; CRP, C-reactive protein; NHS, Nurses’ Health Study; NSAID,
nonsteroidal antiinﬂammatory drug; HDL, high-density lipoprotein;
BMI, body mass index.
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HbA1c was signiﬁcantly associated with risk of incident CHD
among both women and men. Although a 0.5%-increment
decrease in HbA1c in patients undergoing treatment for
diabetes
39 and morbid obesity
40 has proven health beneﬁts,
there are no published experimental trials that show a similar
decrease in HbA1c leads to a reduction in CHD or CVD end
points in the general population. Nevertheless, the most
effective ways of reducing HbA1c, namely dietary changes,
increased physical activity, and weight loss, have been shown
to have beneﬁcial effects on other cardiovascular risk factors.
HbA1c in nondiabetic individuals may be successfully reduced
through nonpharmacologic lifestyle interventions, as demon-
strated in the Finnish Diabetes Prevention Study,
41,42 Diabe-
tes Prevention Program
43 and Outcomes Study,
44 and Look
AHEAD study.
45 In a small intervention study of nondiabetic
obese males, the mean HbA1c levels were signiﬁcantly lower
after the weight loss intervention compared with the before-
intervention levels (4.9% versus 5.1%),
46 and in a randomized
controlled trial of male construction workers, lifestyle inter-
vention aimed at energy balance was signiﬁcantly associated
with improved cardiovascular risk factors, including body
weight, blood pressure, and lipid and HbA1c levels.
47 Although
whether lowering HbA1c lowers risk of future CHD among
nondiabetic individuals has not been directly tested, working
to optimize cardiovascular health in individuals with mildly
higher HbA1c seems prudent and clinically important.
Strengthsofthepresentanalysisincludethelongdurationof
follow-up, the prospective nature of the data collection,
replication in a second cohort, and comprehensive lifestyle
and health factor data used for detailed multivariable adjust-
ment.Afewlimitationsshouldbeaddressed.First,thepotential
exists for measurement error in lifestyle data ascertained from
self-reported questionnaires. However, the reproducibility and
validity of the self-reported questionnaire have been well-
documentedinthese2populationsofhealthprofessionals.
15,48
Second, our study was conducted in 2 cohorts of middle-aged,
predominantly white health professionals and may not be
generalizeable to other populations. However, the relationship
between HbA1c and CHD risk was similar in a recent commu-
nity-based studyamongwhites andAfrican Americans.
29Third,
we only had a single measurement of HbA1c at baseline and did
not have glucose measurements. However, one advantage of
using HbA1c is that it is stable in stored samples and reﬂects
glycemic control over an average of 3 months rather than
measures such as glucose, which are susceptible to daily
ﬂuctuations.
49Inaddition,weobservedexcellentwithin-person
reproducibility in repeated samples measured 3 years apart
and conducted additional analyses correcting for potential
changes in the baseline measurement over time.
In summary, we found that HbA1c is a predictor of CHD risk
among apparently healthy women and men without diabetes
and with HbA1c <6.5%. Further examination is warranted to
determine whether reducing HbA1c among otherwise inter-
mediate- and low-risk individuals without diagnosed diabetes
will prevent incident CHD events.
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